Jingjing Zou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jingjing Zou has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Z. LaCroix
Division of Epidemiology, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA
5 shared publications - Andrew M. Lowy
Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California San Diego, San Diego, California, USA
4 shared publications - Loki Natarajan
Herbert Wertheim School of Public Health, UC San Diego , La Jolla, CA
4 shared publications - Chongzhi Di
Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA
3 shared publications - Dannielle D. Engle
Salk Institute for Biological Studies, La Jolla, California, USA
3 shared publications - Hervé Tiriac
Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California San Diego, San Diego, California, USA
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Timing and Magnitude Changes in Wearable-Measured Daily Physical Activity and Physical Function in Older Women: Longitudinal Cohort Study (Preprint)
BACKGROUND Wearable accelerometers can record minute-level physical activity (PA) repeatedly over time. Longitudinal change is usually summarized as a change in daily activity volume, which discards when during the day activity is gained or lost. A representation of within-person change in the full daily activity curve could provide more informative measures of functional aging. OBJECTIVE This study aimed to characterize within-person changes in the timing and magnitude of daily PA in older women and to examine whether features of these changes were associated with physical function (PF). METHODS We analyzed hip-worn accelerometry from the Objective Physical Activity and Cardiovascular Health (OPACH) baseline assessment and two Women’s Health Initiative Strong and Healthy (WHISH) follow-up assessments in 1,730 women with at least two consecutive valid assessments. Change between smoothed diurnal PA curves (6:00 a.m. to midnight) was modeled as a Riemannian deformation, whose initial momenta represent timing- and magnitude-related changes. Multivariate functional principal component analysis (MFPCA) summarized these changes as participant-level principal component (PC) scores. Linear mixed-effects models related PC scores and deformation energy, a nondirectional measure of pattern change, to RAND-36 PF, adjusting for baseline PF and covariates. A second model replaced PC scores with the change in net area under the activity curve (Δnet-AUC ), a volume summary. RESULTS On average, activity declined across the day from baseline to WHISH wave 1 (baseline–W1) and from WHISH wave 1 to wave 2 (W1–W2), with morning activity shifted later, and activity after about 10:20 a.m. shifted earlier. Fifteen PCs captured at least 90% of total variance in each transition. Of the variance captured by these 15 PCs, the first PC (PC1) accounted for 22.4% in baseline–W1 and 20.8% in W1–W2. Higher PC1 scores reflected residual upward shifts in activity, especially between 10 a.m. and 7 p.m., and was highly correlated with Δnet-AUC (r=0.9). Among 1,157 participants with complete data, PC1 scores were positively associated with PF scores after adjustment for baseline PF and covariates (P<.001). An interquartile increase in PC1 corresponded to a 1.3-point higher PF score (SE = 0.33). Deformation energy was more strongly associated with PF in W1–W2 than in baseline–W1 (interaction β = 387.4, SE = 129.84, P=.003), and this interaction persisted in the model with Δnet-AUC (P=.005). CONCLUSIONS Riemannian deformation analysis of repeated wearable accelerometry characterized changes in when and how much older women were active. The dominant mode of change largely tracked activity volume and was associated with PF. Jointly modeling changes in activity timing and magnitude provides a framework for studying functional aging using longitudinal wearable data.
- 23 October 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessTiming and Magnitude Changes in Wearable-Measured Daily Physical Activity and Physical Function in Older Women: Longitudinal Cohort Study (Preprint)
BACKGROUND Wearable accelerometers can record minute-level physical activity (PA) repeatedly over time. Longitudinal change is usually summarized as a change in daily activity volume, which discards when during the day activity is gained or lost. A representation of within-person change in the full daily activity curve could provide more informative measures of functional aging. OBJECTIVE This study aimed to characterize within-person changes in the timing and magnitude of daily PA in older women and to examine whether features of these changes were associated with physical function (PF). METHODS We analyzed hip-worn accelerometry from the Objective Physical Activity and Cardiovascular Health (OPACH) baseline assessment and two Women’s Health Initiative Strong and Healthy (WHISH) follow-up assessments in 1,730 women with at least two consecutive valid assessments. Change between smoothed diurnal PA curves (6:00 a.m. to midnight) was modeled as a Riemannian deformation, whose initial momenta represent timing- and magnitude-related changes. Multivariate functional principal component analysis (MFPCA) summarized these changes as participant-level principal component (PC) scores. Linear mixed-effects models related PC scores and deformation energy, a nondirectional measure of pattern change, to RAND-36 PF, adjusting for baseline PF and covariates. A second model replaced PC scores with the change in net area under the activity curve (Δnet-AUC ), a volume summary. RESULTS On average, activity declined across the day from baseline to WHISH wave 1 (baseline–W1) and from WHISH wave 1 to wave 2 (W1–W2), with morning activity shifted later, and activity after about 10:20 a.m. shifted earlier. Fifteen PCs captured at least 90% of total variance in each transition. Of the variance captured by these 15 PCs, the first PC (PC1) accounted for 22.4% in baseline–W1 and 20.8% in W1–W2. Higher PC1 scores reflected residual upward shifts in activity, especially between 10 a.m. and 7 p.m., and was highly correlated with Δnet-AUC (r=0.9). Among 1,157 participants with complete data, PC1 scores were positively associated with PF scores after adjustment for baseline PF and covariates (P<.001). An interquartile increase in PC1 corresponded to a 1.3-point higher PF score (SE = 0.33). Deformation energy was more strongly associated with PF in W1–W2 than in baseline–W1 (interaction β = 387.4, SE = 129.84, P=.003), and this interaction persisted in the model with Δnet-AUC (P=.005). CONCLUSIONS Riemannian deformation analysis of repeated wearable accelerometry characterized changes in when and how much older women were active. The dominant mode of change largely tracked activity volume and was associated with PF. Jointly modeling changes in activity timing and magnitude provides a framework for studying functional aging using longitudinal wearable data.
- Open Access
CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma
Durable therapeutic efficacy remains a major barrier to improving outcomes for patients with pancreatic ductal adenocarcinoma (PDAC). An immunosuppressive tumor microenvironment (TME) is a hallmark of PDAC and has been demonstrated to be a dominant driver of therapeutic resistance. The aberrant glycan CA19-9 is prevalent in PDAC and drives tumor progression, but the paracrine mechanisms by which it contributes to TME remodeling are unknown. To address this, we mapped TME changes and performed functional analyses using a genetically engineered mouse model (GEMM) harboring Kras G12D mutation and inducible CA19-9 expression. Elevation of CA19-9 led to expansion of antigen-presenting cancer associated fibroblasts (apCAFs) and regulatory T cells (Tregs), which can drive immunosuppression. Antibody blockade of CA19 -9 resulted in significant restoration of normal histology and decreased apCAF and Treg populations. We dissected the paracrine signaling mechanisms that drive this TME remodeling in vitro using mouse and human organoid mono- and co-culture models as well as in vivo using GEMMs and syngeneic orthotopic transplantation models. CA19-9 induced IL1a and TGFb expression, reprogramming pancreatic mesothelial cells into apCAFs in vitro , which in turn directly ligated naïve Cd4 + T cells resulting in Treg differentiation in co-cultures. Antibody blockade of IL1a and TGFb in mice led to reduced apCAF and Treg differentiation. We previously reported that CA19-9 modification of the secreted Fbln3 protein increased Egfr engagement and now find that the induction of IL1a and TGFb expression by CA19-9 is dependent on Fbln3 hyperactivation of EGFR signaling. Genetic depletion of Fbln3 led to reduced tumor progression and increased Cd8 + T cell infiltration in mice. Together these findings identify a previously unknown signaling axis driving immunosuppressive phenotypes in PDAC, uncovering multiple potential nodes to relieve the immunosuppressive pressures within the PDAC TME.
Open AccessCA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma
Durable therapeutic efficacy remains a major barrier to improving outcomes for patients with pancreatic ductal adenocarcinoma (PDAC). An immunosuppressive tumor microenvironment (TME) is a hallmark of PDAC and has been demonstrated to be a dominant driver of therapeutic resistance. The aberrant glycan CA19-9 is prevalent in PDAC and drives tumor progression, but the paracrine mechanisms by which it contributes to TME remodeling are unknown. To address this, we mapped TME changes and performed functional analyses using a genetically engineered mouse model (GEMM) harboring Kras G12D mutation and inducible CA19-9 expression. Elevation of CA19-9 led to expansion of antigen-presenting cancer associated fibroblasts (apCAFs) and regulatory T cells (Tregs), which can drive immunosuppression. Antibody blockade of CA19 -9 resulted in significant restoration of normal histology and decreased apCAF and Treg populations. We dissected the paracrine signaling mechanisms that drive this TME remodeling in vitro using mouse and human organoid mono- and co-culture models as well as in vivo using GEMMs and syngeneic orthotopic transplantation models. CA19-9 induced IL1a and TGFb expression, reprogramming pancreatic mesothelial cells into apCAFs in vitro , which in turn directly ligated naïve Cd4 + T cells resulting in Treg differentiation in co-cultures. Antibody blockade of IL1a and TGFb in mice led to reduced apCAF and Treg differentiation. We previously reported that CA19-9 modification of the secreted Fbln3 protein increased Egfr engagement and now find that the induction of IL1a and TGFb expression by CA19-9 is dependent on Fbln3 hyperactivation of EGFR signaling. Genetic depletion of Fbln3 led to reduced tumor progression and increased Cd8 + T cell infiltration in mice. Together these findings identify a previously unknown signaling axis driving immunosuppressive phenotypes in PDAC, uncovering multiple potential nodes to relieve the immunosuppressive pressures within the PDAC TME.
- Open Access
CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation
Pancreatic ductal adenocarcinoma (PDAC) frequently metastasizes to the liver, which drives patient mortality. CA19-9 is elevated in most PDAC tumors and is widely used as a clinical biomarker. Elevated serum levels are associated with poor outcomes. However, whether CA19-9 functionally contributes to metastatic progression has not been fully defined, in part because mice lack endogenous CA19-9 expression. Here, using syngeneic murine PDAC cells engineered to express CA19-9, we investigated its functional role in liver metastasis. In splenic injection models, CA19-9 expression markedly increased liver metastatic burden by promoting both metastatic seeding and subsequent metastatic outgrowth. In vitro , CA19-9 enhanced tumor cell adhesion to endothelial cells through interaction with E-selectin. Metastatic seeding of CA19-9-expressing cells was reduced by genetic deletion of E-selectin or antibody neutralization of either CA19-9 or E-selectin in vivo . Therapeutic targeting of CA19-9 with a neutralizing antibody markedly reduced liver metastatic burden after metastatic seeding. CA19-9 expression increased AKT signaling in PDAC cells and liver metastases, and CA19-9 levels correlated with AKT activation in human PDAC tissues. These findings show that CA19-9 promotes PDAC liver metastasis through E-selectin-dependent metastatic seeding and AKT-associated metastatic outgrowth, highlighting CA19-9 as a functional mediator of PDAC metastasis and a potential therapeutic target.
Open AccessCA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation
Pancreatic ductal adenocarcinoma (PDAC) frequently metastasizes to the liver, which drives patient mortality. CA19-9 is elevated in most PDAC tumors and is widely used as a clinical biomarker. Elevated serum levels are associated with poor outcomes. However, whether CA19-9 functionally contributes to metastatic progression has not been fully defined, in part because mice lack endogenous CA19-9 expression. Here, using syngeneic murine PDAC cells engineered to express CA19-9, we investigated its functional role in liver metastasis. In splenic injection models, CA19-9 expression markedly increased liver metastatic burden by promoting both metastatic seeding and subsequent metastatic outgrowth. In vitro , CA19-9 enhanced tumor cell adhesion to endothelial cells through interaction with E-selectin. Metastatic seeding of CA19-9-expressing cells was reduced by genetic deletion of E-selectin or antibody neutralization of either CA19-9 or E-selectin in vivo . Therapeutic targeting of CA19-9 with a neutralizing antibody markedly reduced liver metastatic burden after metastatic seeding. CA19-9 expression increased AKT signaling in PDAC cells and liver metastases, and CA19-9 levels correlated with AKT activation in human PDAC tissues. These findings show that CA19-9 promotes PDAC liver metastasis through E-selectin-dependent metastatic seeding and AKT-associated metastatic outgrowth, highlighting CA19-9 as a functional mediator of PDAC metastasis and a potential therapeutic target.
- 1 January 2026
- Published by Human Kinetics in Journal for the Measurement of Physical Behaviour
- Vol. 9 (1)
Validating the Longitudinal Assessment of Sedentary Behavior in a Randomized Controlled Trial via a Deep-Learning Algorithm
Background : Sedentary behavior (SB) is a risk factor for cardiometabolic disease. Existing cut points of hip-worn accelerometers to quantify SB underestimate sedentary bout durations by ignoring posture. To address this, we previously developed Convolutional Neural Network Hip Accelerometer Posture (CHAP), a deep-learning algorithm that predicts sitting and breaks from sitting. In this study, we applied CHAP to a randomized controlled trial to externally validate its accuracy for classifying sitting versus nonsitting and estimating intervention-related changes in SB. Methods : CHAP was applied to 30-Hz triaxial hip-worn ActiGraph-GT3X+ (AG) accelerometer data from free-living postmenopausal women who are overweight (≥55 years) in the Rise for Health RCT ( n = 406). CHAP-predicted SB accuracy (e.g., sensitivity) and daily pattern metrics (e.g., total sedentary time) were compared with a ground-truth device activPAL (AP) and standard cut-point method (AG100) at two timepoints for intervention arms—Healthy Living (control), Reduce Sitting, and Increase Transitions. Results : CHAP’s SB accuracy metrics were above 84.8%. Mean (standard error, p values) intervention effect estimates (mean change, intervention minus controls) from generalized estimating equation models for (a) total sedentary time were AP 65.1 min/day (16.2, p < .001), CHAP 38.2 min/day (15.4, p = .013), and AG100 0.28 min/day (13.9, p = .98; Reduce Sitting); (b) breaks from SB were AP 22/day (4.3, p < .001), CHAP 4/day (1.5, p = .003), and AG100 p = .860; Increase Transitions). Conclusions : This study validated CHAP on an independent cohort. CHAP exhibited high prediction accuracy, and although less sensitive than AP, CHAP detected changes in SB more effectively than AG100. Thus, CHAP could make a strong contribution to SB intervention research.
- 1 January 2026
- Published by Human Kinetics in Journal for the Measurement of Physical Behaviour
- Vol. 9 (1)
Validating the Longitudinal Assessment of Sedentary Behavior in a Randomized Controlled Trial via a Deep-Learning Algorithm
Background : Sedentary behavior (SB) is a risk factor for cardiometabolic disease. Existing cut points of hip-worn accelerometers to quantify SB underestimate sedentary bout durations by ignoring posture. To address this, we previously developed Convolutional Neural Network Hip Accelerometer Posture (CHAP), a deep-learning algorithm that predicts sitting and breaks from sitting. In this study, we applied CHAP to a randomized controlled trial to externally validate its accuracy for classifying sitting versus nonsitting and estimating intervention-related changes in SB. Methods : CHAP was applied to 30-Hz triaxial hip-worn ActiGraph-GT3X+ (AG) accelerometer data from free-living postmenopausal women who are overweight (≥55 years) in the Rise for Health RCT ( n = 406). CHAP-predicted SB accuracy (e.g., sensitivity) and daily pattern metrics (e.g., total sedentary time) were compared with a ground-truth device activPAL (AP) and standard cut-point method (AG100) at two timepoints for intervention arms—Healthy Living (control), Reduce Sitting, and Increase Transitions. Results : CHAP’s SB accuracy metrics were above 84.8%. Mean (standard error, p values) intervention effect estimates (mean change, intervention minus controls) from generalized estimating equation models for (a) total sedentary time were AP 65.1 min/day (16.2, p < .001), CHAP 38.2 min/day (15.4, p = .013), and AG100 0.28 min/day (13.9, p = .98; Reduce Sitting); (b) breaks from SB were AP 22/day (4.3, p < .001), CHAP 4/day (1.5, p = .003), and AG100 p = .860; Increase Transitions). Conclusions : This study validated CHAP on an independent cohort. CHAP exhibited high prediction accuracy, and although less sensitive than AP, CHAP detected changes in SB more effectively than AG100. Thus, CHAP could make a strong contribution to SB intervention research.
- Open Access
- 26 March 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (3)
Accelerometer-measured physical activity, sedentary behavior, and mortality among cancer survivors: the Women’s Health Accelerometry Collaboration
Background: Data on prospective associations of accelerometer-measured physical activity, sedentary behavior, and mortality among cancer survivors are lacking. Our study examined accelerometer-measured daily physical activity (including light, moderate to vigorous, total, and steps), sedentary behavior (sitting time and mean bout duration), and mortality among cancer survivors in the Women’s Health Accelerometry Collaboration. Methods: Postmenopausal women in the Collaboration who reported a cancer diagnosis at least 1 year prior to wearing an ActiGraph GT3X+ device on the hip for at least 4 of 7 days from 2011 to 2015 were included. Outcomes included all-cause, cancer-related, and cardiovascular disease (CVD)–related mortality. Covariate-adjusted Cox regression estimated hazard ratios (HRs) and 95% CIs for each physical activity and sedentary behavior measure in association with mortality. Results: Overall, 2479 cancer survivors (mean [SD] age, 74.2 [6.7] years) were followed up for 8.3 years. For all-cause mortality (n = 594 cases), every 78.1 minutes per day in light physical activity, 96.5 minutes per day in total physical activity, 102.2 minutes per day in sitting time, and 4.8 minutes in a sitting bout duration had hazard ratios of 0.92 (95% CI = 0.84 to 1.01), 0.89 (95% CI = 0.80 to 0.98), 1.12 (95% CI = 1.02 to 1.24), and 1.04 (95% CI = 0.96 to 1.12), respectively. Linear associations for cancer mortality (n = 168) and CVD mortality (n = 109) were not statistically significant, except for steps (hazard ratio per 2469 steps/d = 0.66, 95% CI = 0.45 to 0.96) and sitting time (hazard ratio = 1.30, 95% CI = 1.02 to 1.67) for CVD mortality. Nonlinear associations showed benefits of moderate to vigorous physical activity (for all-cause and CVD mortality) and steps (all-cause mortality only) maximized at approximately 60 minutes per day and 5000–6000 steps per day, respectively. Conclusions: Among postmenopausal cancer survivors, higher physical activity and lower sedentary behavior was associated with reduced hazards of all-cause and CVD mortality.
- 26 March 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (3)
Open AccessAccelerometer-measured physical activity, sedentary behavior, and mortality among cancer survivors: the Women’s Health Accelerometry Collaboration
Background: Data on prospective associations of accelerometer-measured physical activity, sedentary behavior, and mortality among cancer survivors are lacking. Our study examined accelerometer-measured daily physical activity (including light, moderate to vigorous, total, and steps), sedentary behavior (sitting time and mean bout duration), and mortality among cancer survivors in the Women’s Health Accelerometry Collaboration. Methods: Postmenopausal women in the Collaboration who reported a cancer diagnosis at least 1 year prior to wearing an ActiGraph GT3X+ device on the hip for at least 4 of 7 days from 2011 to 2015 were included. Outcomes included all-cause, cancer-related, and cardiovascular disease (CVD)–related mortality. Covariate-adjusted Cox regression estimated hazard ratios (HRs) and 95% CIs for each physical activity and sedentary behavior measure in association with mortality. Results: Overall, 2479 cancer survivors (mean [SD] age, 74.2 [6.7] years) were followed up for 8.3 years. For all-cause mortality (n = 594 cases), every 78.1 minutes per day in light physical activity, 96.5 minutes per day in total physical activity, 102.2 minutes per day in sitting time, and 4.8 minutes in a sitting bout duration had hazard ratios of 0.92 (95% CI = 0.84 to 1.01), 0.89 (95% CI = 0.80 to 0.98), 1.12 (95% CI = 1.02 to 1.24), and 1.04 (95% CI = 0.96 to 1.12), respectively. Linear associations for cancer mortality (n = 168) and CVD mortality (n = 109) were not statistically significant, except for steps (hazard ratio per 2469 steps/d = 0.66, 95% CI = 0.45 to 0.96) and sitting time (hazard ratio = 1.30, 95% CI = 1.02 to 1.67) for CVD mortality. Nonlinear associations showed benefits of moderate to vigorous physical activity (for all-cause and CVD mortality) and steps (all-cause mortality only) maximized at approximately 60 minutes per day and 5000–6000 steps per day, respectively. Conclusions: Among postmenopausal cancer survivors, higher physical activity and lower sedentary behavior was associated with reduced hazards of all-cause and CVD mortality.
- 20 February 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (6) , 705-715
Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations
PURPOSE: Mucinous neoplasms of the gastrointestinal tract are characterized by a propensity for metastasis to the peritoneum, resulting in peritoneal mucinous carcinomatosis (PMC). A subset of these tumors, most often originating in the appendix, harbor mutations in the GNAS oncogene. While the natural history of GNAS -mutant PMC varies, patient outcomes are generally poor, as is response to cytotoxic chemotherapy. The purpose of this study was to evaluate the clinical efficacy of single-agent palbociclib, a cyclin-dependent kinase (CDK)4/6 inhibitor, in patients with GNAS -mutant PMC. PATIENTS AND METHODS: We enrolled 16 patients with PMC in a single-arm personalized cancer therapy trial. For all patients, tumor tissue and/or circulating tumor DNA genomic profiling using next-generation sequencing and, when possible, PD-L1 expression, tumor mutational burden, and microsatellite instability status was assessed. Twelve of 16 patients had previous disease progression on at least one previous line of chemotherapy. The primary tumor was appendix in 13 patients, unknown in two patients, and pancreas in one patient. Eleven cases were classified as low grade, and five as high grade. RESULTS: In 13 of 16 patients, we observed a decrease in carcinoembryonic antigen (CEA), and in six patients, the CEA declined by >50%. As measured by clinical and modified peritoneal RECIST criteria, 50% of evaluable patients had stable disease after 12 months of palbociclib. At a median follow-up of 17.6 months, median survival has not been reached. Clinical response to CDK4/6 inhibition was mirrored in tumors with GNAS mutation and mucinous histology using an ex vivo preclinical platform. CONCLUSION: CDK4/6 inhibition with palbociclib had clinical activity in PMC characterized by mutations in GNAS that was superior to that previously reported with cytotoxic chemotherapy. CDK4/6 inhibition is a novel therapeutic strategy worthy of further evaluation in this subgroup of gastrointestinal neoplasms.
- 20 February 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (6) , 705-715
Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations
PURPOSE: Mucinous neoplasms of the gastrointestinal tract are characterized by a propensity for metastasis to the peritoneum, resulting in peritoneal mucinous carcinomatosis (PMC). A subset of these tumors, most often originating in the appendix, harbor mutations in the GNAS oncogene. While the natural history of GNAS -mutant PMC varies, patient outcomes are generally poor, as is response to cytotoxic chemotherapy. The purpose of this study was to evaluate the clinical efficacy of single-agent palbociclib, a cyclin-dependent kinase (CDK)4/6 inhibitor, in patients with GNAS -mutant PMC. PATIENTS AND METHODS: We enrolled 16 patients with PMC in a single-arm personalized cancer therapy trial. For all patients, tumor tissue and/or circulating tumor DNA genomic profiling using next-generation sequencing and, when possible, PD-L1 expression, tumor mutational burden, and microsatellite instability status was assessed. Twelve of 16 patients had previous disease progression on at least one previous line of chemotherapy. The primary tumor was appendix in 13 patients, unknown in two patients, and pancreas in one patient. Eleven cases were classified as low grade, and five as high grade. RESULTS: In 13 of 16 patients, we observed a decrease in carcinoembryonic antigen (CEA), and in six patients, the CEA declined by >50%. As measured by clinical and modified peritoneal RECIST criteria, 50% of evaluable patients had stable disease after 12 months of palbociclib. At a median follow-up of 17.6 months, median survival has not been reached. Clinical response to CDK4/6 inhibition was mirrored in tumors with GNAS mutation and mucinous histology using an ex vivo preclinical platform. CONCLUSION: CDK4/6 inhibition with palbociclib had clinical activity in PMC characterized by mutations in GNAS that was superior to that previously reported with cytotoxic chemotherapy. CDK4/6 inhibition is a novel therapeutic strategy worthy of further evaluation in this subgroup of gastrointestinal neoplasms.
- 27 August 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Neural Networks and Learning Systems
- Vol. 36 (7) , 13512-13526
Kernel Masked Image Modeling Through the Lens of Theoretical Understanding
Masked image modeling (MIM) has been considered as the state-of-the-art (SOTA) self-supervised learning (SSL) technique in terms of visual pretraining. The impressive generalization ability of MIM also paves the way for the remarkable success of large-scale vision foundation models. In this article, we further discuss the validity and advantages of implementing MIM techniques in the reproducing kernel Hilbert spaces (RKHSs) and we associate the analysis with a novel MIM method named R-MIM (short for RKHS-MIM). Through the careful construction of an augmentation graph and by using spectral decomposition techniques, we establish a systematic theoretical understanding between the proposed R-MIM’s generalization ability and the choice of kernel function used during training. Specifically, we reach a conclusion that both of the local Lipschitz constant of the resultant R-MIM model and the corresponding expected pretraining error can have a strong composite effect on bounding downstream task error, depending on the kernel options. We demonstrate that under mild mathematical assumptions, R-MIM method is guaranteed to return a lower bound on downstream tasks in comparison to vanilla MIM techniques, such as masked autoencoder (MAE) and SimMIM. Empirical justification well corroborates our theoretical hypothesis and analysis in showing the superior generalization of the proposed R-MIM and the theoretical link to kernel choices. The code is available at: https://github.com/yurui-q/R-MIM.
- 27 August 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Neural Networks and Learning Systems
- Vol. 36 (7) , 13512-13526
Kernel Masked Image Modeling Through the Lens of Theoretical Understanding
Masked image modeling (MIM) has been considered as the state-of-the-art (SOTA) self-supervised learning (SSL) technique in terms of visual pretraining. The impressive generalization ability of MIM also paves the way for the remarkable success of large-scale vision foundation models. In this article, we further discuss the validity and advantages of implementing MIM techniques in the reproducing kernel Hilbert spaces (RKHSs) and we associate the analysis with a novel MIM method named R-MIM (short for RKHS-MIM). Through the careful construction of an augmentation graph and by using spectral decomposition techniques, we establish a systematic theoretical understanding between the proposed R-MIM’s generalization ability and the choice of kernel function used during training. Specifically, we reach a conclusion that both of the local Lipschitz constant of the resultant R-MIM model and the corresponding expected pretraining error can have a strong composite effect on bounding downstream task error, depending on the kernel options. We demonstrate that under mild mathematical assumptions, R-MIM method is guaranteed to return a lower bound on downstream tasks in comparison to vanilla MIM techniques, such as masked autoencoder (MAE) and SimMIM. Empirical justification well corroborates our theoretical hypothesis and analysis in showing the superior generalization of the proposed R-MIM and the theoretical link to kernel choices. The code is available at: https://github.com/yurui-q/R-MIM.
- Open Access
- 9 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (1)
The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient–derived organoids
The use of patient-derived organoids (PDOs) to characterize therapeutic sensitivity and resistance is a promising precision medicine approach, and its potential to inform clinical decisions is now being tested in several large multiinstitutional clinical trials. PDOs are cultivated in the extracellular matrix from basement membrane extracts (BMEs) that are most commonly acquired commercially. Each clinical site utilizes distinct BME lots and may be restricted due to the availability of commercial BME sources. However, the effect of different sources of BMEs on organoid drug response is unknown. Here, we tested the effect of BME source on proliferation, drug response, and gene expression in mouse and human pancreatic ductal adenocarcinoma (PDA) organoids. Both human and mouse organoids displayed increased proliferation in Matrigel compared with Cultrex and UltiMatrix. However, we observed no substantial effect on drug response when organoids were cultured in Matrigel, Cultrex, or UltiMatrix. We also did not observe major shifts in gene expression across the different BME sources, and PDOs maintained their classical or basal-like designation. Overall, we found that the BME source (Matrigel, Cultrex, UltiMatrix) does not shift PDO dose-response curves or drug testing results, indicating that PDO pharmacotyping is a robust approach for precision medicine.
- 9 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (1)
Open AccessThe effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient–derived organoids
The use of patient-derived organoids (PDOs) to characterize therapeutic sensitivity and resistance is a promising precision medicine approach, and its potential to inform clinical decisions is now being tested in several large multiinstitutional clinical trials. PDOs are cultivated in the extracellular matrix from basement membrane extracts (BMEs) that are most commonly acquired commercially. Each clinical site utilizes distinct BME lots and may be restricted due to the availability of commercial BME sources. However, the effect of different sources of BMEs on organoid drug response is unknown. Here, we tested the effect of BME source on proliferation, drug response, and gene expression in mouse and human pancreatic ductal adenocarcinoma (PDA) organoids. Both human and mouse organoids displayed increased proliferation in Matrigel compared with Cultrex and UltiMatrix. However, we observed no substantial effect on drug response when organoids were cultured in Matrigel, Cultrex, or UltiMatrix. We also did not observe major shifts in gene expression across the different BME sources, and PDOs maintained their classical or basal-like designation. Overall, we found that the BME source (Matrigel, Cultrex, UltiMatrix) does not shift PDO dose-response curves or drug testing results, indicating that PDO pharmacotyping is a robust approach for precision medicine.
- Open Access
- 24 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-13
Optimizing campus-wide COVID-19 test notifications with interpretable wastewater time-series features using machine learning models
During the COVID-19 pandemic, wastewater surveillance of the SARS CoV-2 virus has been demonstrated to be effective for population surveillance at the county level down to the building level. At the University of California, San Diego, daily high-resolution wastewater surveillance conducted at the building level is being used to identify potential undiagnosed infections and trigger notification of residents and responsive testing, but the optimal determinants for notifications are unknown. To fill this gap, we propose a pipeline for data processing and identifying features of a series of wastewater test results that can predict the presence of COVID-19 in residences associated with the test sites. Using time series of wastewater results and individual testing results during periods of routine asymptomatic testing among UCSD students from 11/2020 to 11/2021, we develop hierarchical classification/decision tree models to select the most informative wastewater features (patterns of results) which predict individual infections. We find that the best predictor of positive individual level tests in residence buildings is whether or not the wastewater samples were positive in at least 3 of the past 7 days. We also demonstrate that the tree models outperform a wide range of other statistical and machine models in predicting the individual COVID-19 infections while preserving interpretability. Results of this study have been used to refine campus-wide guidelines and email notification systems to alert residents of potential infections.
- 24 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-13
Open AccessOptimizing campus-wide COVID-19 test notifications with interpretable wastewater time-series features using machine learning models
During the COVID-19 pandemic, wastewater surveillance of the SARS CoV-2 virus has been demonstrated to be effective for population surveillance at the county level down to the building level. At the University of California, San Diego, daily high-resolution wastewater surveillance conducted at the building level is being used to identify potential undiagnosed infections and trigger notification of residents and responsive testing, but the optimal determinants for notifications are unknown. To fill this gap, we propose a pipeline for data processing and identifying features of a series of wastewater test results that can predict the presence of COVID-19 in residences associated with the test sites. Using time series of wastewater results and individual testing results during periods of routine asymptomatic testing among UCSD students from 11/2020 to 11/2021, we develop hierarchical classification/decision tree models to select the most informative wastewater features (patterns of results) which predict individual infections. We find that the best predictor of positive individual level tests in residence buildings is whether or not the wastewater samples were positive in at least 3 of the past 7 days. We also demonstrate that the tree models outperform a wide range of other statistical and machine models in predicting the individual COVID-19 infections while preserving interpretability. Results of this study have been used to refine campus-wide guidelines and email notification systems to alert residents of potential infections.
- 9 January 2023
- Published by Elsevier in Brachytherapy
- Vol. 22 (3) , 317-324
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer
- 9 January 2023
- Published by Elsevier in Brachytherapy
- Vol. 22 (3) , 317-324
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer